Leerink Partnrs Has Bullish Forecast for PTCT Q1 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for PTC Therapeutics in a report issued on Tuesday, May 6th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings of $10.04 per share for the quarter, up from their previous estimate of ($1.47). The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. Leerink Partnrs also issued estimates for PTC Therapeutics’ Q2 2025 earnings at ($0.96) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at $8.89 EPS and FY2026 earnings at ($2.99) EPS.

PTC Therapeutics (NASDAQ:PTCT) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $9.19. The business had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $437.16 million. During the same quarter last year, the firm earned ($1.20) earnings per share. The business’s quarterly revenue was down 9.6% on a year-over-year basis.

Other equities analysts also recently issued research reports about the company. Royal Bank of Canada boosted their target price on PTC Therapeutics from $57.00 to $58.00 and gave the company an “outperform” rating in a research report on Wednesday. Cantor Fitzgerald cut their price objective on shares of PTC Therapeutics from $113.00 to $112.00 and set an “overweight” rating on the stock in a research report on Wednesday. Barclays lowered their target price on shares of PTC Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a report on Thursday. Scotiabank assumed coverage on shares of PTC Therapeutics in a research report on Friday, March 7th. They issued a “sector perform” rating and a $55.00 price objective on the stock. Finally, StockNews.com upgraded PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, PTC Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.92.

PTC Therapeutics Price Performance

Shares of NASDAQ PTCT opened at $42.54 on Friday. PTC Therapeutics has a 1-year low of $28.72 and a 1-year high of $58.38. The business’s 50 day moving average is $49.01 and its two-hundred day moving average is $46.96. The stock has a market capitalization of $3.37 billion, a P/E ratio of -7.16 and a beta of 0.52.

Institutional Trading of PTC Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of PTCT. Vanguard Group Inc. lifted its stake in shares of PTC Therapeutics by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 9,178,822 shares of the biopharmaceutical company’s stock worth $414,332,000 after purchasing an additional 53,688 shares during the last quarter. Toronto Dominion Bank purchased a new stake in shares of PTC Therapeutics during the fourth quarter valued at about $148,363,000. Janus Henderson Group PLC boosted its holdings in shares of PTC Therapeutics by 24.4% in the 4th quarter. Janus Henderson Group PLC now owns 2,325,915 shares of the biopharmaceutical company’s stock valued at $105,015,000 after buying an additional 455,698 shares in the last quarter. Point72 Asset Management L.P. grew its position in shares of PTC Therapeutics by 150.6% in the 4th quarter. Point72 Asset Management L.P. now owns 1,443,362 shares of the biopharmaceutical company’s stock worth $65,153,000 after buying an additional 867,502 shares during the last quarter. Finally, Nuveen Asset Management LLC raised its stake in shares of PTC Therapeutics by 34.0% during the 4th quarter. Nuveen Asset Management LLC now owns 1,077,794 shares of the biopharmaceutical company’s stock worth $48,652,000 after acquiring an additional 273,638 shares in the last quarter.

Insiders Place Their Bets

In other news, EVP Lee Scott Golden sold 897 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $46.95, for a total transaction of $42,114.15. Following the transaction, the executive vice president now directly owns 75,997 shares in the company, valued at approximately $3,568,059.15. This trade represents a 1.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Mark Elliott Boulding sold 1,333 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total transaction of $66,783.30. Following the transaction, the vice president now directly owns 105,515 shares in the company, valued at approximately $5,286,301.50. The trade was a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,305 shares of company stock worth $1,682,755 in the last ninety days. 5.50% of the stock is owned by company insiders.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.